PROPEL SINUS IMPLANT 70011

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a company representative,health report with the FDA on 2017-02-01 for PROPEL SINUS IMPLANT 70011 manufactured by Intersect Ent.

Event Text Entries

[66326566] The patient's granulomatous reaction is likely due to a delayed foreign body/allergen-mediated reaction to a component or components of the sinus implant. It is suspect the patient has a previously undiagnosed auto-immune or hypersensitivity disorder. Foreign body reaction is a known risk in patients who are susceptible to this type of reaction. The patients' weight and the lot number(s) of the devices are not known to the manufacturer. The device was not available for evaluation as it was not returned to the manufacturer. Risks associated with the use of this sinus implant are anticipated to be similar to those experienced by patients who undergo placement of other sinus implants or packing. Foreign body reaction may occur as is possible with most surgical adjuncts. The following is being provided as this device is a combination product: name: propel or propel mini (populate as appropriate), dose, frequency & route used: (1) 370 ug implant, diagnosis for use: sinus surgery, combination product -yes. Reference mfr 3008301917-2017-00003 for first implant in the second event. Reference mfr 3008301917-2017-00001 and mfr 3008301917-2017-00002 for the implants in the initial event. .
Patient Sequence No: 1, Text Type: N, H10


[66326567] On day 1, the patient underwent a sinus procedure during which sinus implants were placed bilaterally in the ethmoid sinuses. Septal splints of unknown manufacturer were also placed bilaterally. No sinus implant device malfunction or patient injury is noted to have occurred during the patient's initial procedure. Day 6, the patient was seen by the surgeon for a routine post-operative visit, at which point the septal splints were removed, and per report, the implants were left in place. At that time, there was mild bleeding upon removal of the splints, and a small amount of inflammatory tissue was present, both were within normal expectations. Two days later, patient presented with epistaxis and was taken back to the or. During that procedure it was noted that the patient had "extensive granulation tissue," a "large blood clot," and a posterior bleed. The surgeon elected to remove the sinus implants and they were replaced bilaterally with new ones. The following night the patient reported having a "big bleed" and was seen by the surgeon in her office the next day. The patient was examined endoscopically and observed that the source of the patient's bleed (the prior night) was near the sphenoid, "extensive granulation tissue around the stents bilaterally and fibrinous middle turbinates adhered to the lateral walls. " the physician removed the bilateral implants and debrided the fibrinous tissue encompassing the implants to remove the obstruction of the ethmoid cavity. Patients' event is completely resolved.
Patient Sequence No: 1, Text Type: D, B5


[69129501] Corrected data: event description: corrected sinus procedure to surgical sinus procedure, corrected day 6 to day 8, corrected the day the patient reported a "big bleed" from the following night to two days later. Manufacturer narrative: the physician confirmed there was no causal relationship of epistaxis with the sinus implants.
Patient Sequence No: 1, Text Type: N, H10


[69129502] On day 1 the patient underwent a surgical sinus procedure during which sinus implants were placed bilaterally in the ethmoid sinuses. Septal splints of unknown manufacturer were also placed bilaterally. No sinus implant device malfunction or patient injury is noted to have occurred during the patient's initial procedure. Day 8, the patient was seen by the surgeon for a routine post-operative visit, at which point the septal splints were removed, and per report, the implants were left in place. At that time, there was mild bleeding upon removal of the splints, and a small amount of inflammatory tissue was present, both were within normal expectations. Two days later, patient presented with epistaxis and was taken back to the or. During that procedure it was noted that the patient had "extensive granulation tissue," a "large blood clot," and a posterior bleed. The surgeon elected to remove the sinus implants and they were replaced bilaterally with new ones. Two days later, the patient reported having a "big bleed" and was seen by the surgeon in her office the next day. The patient was examined endoscopically and observed that the source of the patient's bleed (the prior night) was near the sphenoid, "extensive granulation tissue around the stents bilaterally and fibrinous middle turbinates adhered to the lateral walls. " the physician removed the bilateral implants and debrided the fibrinous tissue encompassing the implants to remove the obstruction of the ethmoid cavity. Patients' event is completely resolved.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number3008301917-2017-00004
MDR Report Key6294965
Report SourceCOMPANY REPRESENTATIVE,HEALTH
Date Received2017-02-01
Date of Report2017-01-05
Date of Event2016-12-27
Date Mfgr Received2017-02-08
Date Added to Maude2017-02-01
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactMRS AMY WOLBECK
Manufacturer Street1555 ADAMS DR
Manufacturer CityMENLO PARK CA 94025
Manufacturer CountryUS
Manufacturer Postal94025
Manufacturer Phone6506412115
Manufacturer G1INTERSECT ENT
Manufacturer Street1555 ADAMS DR
Manufacturer CityMENLO PARK CA 94025
Manufacturer CountryUS
Manufacturer Postal Code94025
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NamePROPEL SINUS IMPLANT
Generic NamePROPEL SINUS IMPLANT
Product CodeOWO
Date Received2017-02-01
Model Number70011
OperatorPHYSICIAN
Device AvailabilityN
Device AgeDA
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerINTERSECT ENT
Manufacturer Address1555 ADAMS DR MENLO PARK CA 94025 US 94025


Patients

Patient NumberTreatmentOutcomeDate
101. Required No Informationntervention 2017-02-01

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.